Diamedica Therapeutics Inc.
SEC CIK 1401040 · DMAX · last insider filing 2026-06-03
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Kuntz Richard | Director | filed 2023 - 2026 |
| O'Connor Daniel J. | Director | filed 2025 - 2026 |
| Lewis Tanya | Director | filed 2023 - 2026 |
| Giuffre Randall Michael | Director | filed 2018 - 2026 |
| Parsons James T. | Director | filed 2018 - 2026 |
| Pauls Dietrich John | Director · President and CEO | filed 2018 - 2026 |
| Semba Charles Pauling | Director | filed 2021 - 2026 |
| Pilnik Richard D. | Director | filed 2018 - 2025 |
| Burroughs Amy L. | Director | filed 2021 - 2023 |
| Xiao Zhenyu | Director | filed 2018 - 2019 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Kellen Scott | CFO and Secretary | filed 2018 - 2026 |
| Krop Julie | Chief Medical Officer | filed 2025 - 2026 |
| Wambeke David J. | Chief Business Officer | filed 2023 - 2025 |
| Cundari Dominic R | Chief Commercial Officer | filed 2022 - 2024 |
| Lorianne Masuoka K. | Chief Medical Officer | filed 2024 - 2024 |
| Gruis Kirsten L | Chief Medical Officer | filed 2022 - 2023 |
| Daves Julie Vanorsdel | SVP Clinical Development Oper. | filed 2022 - 2023 |
| Alcorn Harry W JR | Senior VP, Clinical Operations | filed 2018 - 2021 |
| Gilman Sydney A. | VP, Regulatory Affairs | filed 2019 - 2021 |
| Verdoorn Todd A. | Chief Scientific Officer | filed 2018 - 2019 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.